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Introduction {#sec1}
============

Parkinson disease (PD) is a progressive and incurable neurodegenerative disease, affecting 1%--2% of people older than 60 years ([@bib49]). Patients suffering from PD exhibit characteristic motor dysfunctions, including rigidity, akinesia, tremor, and postural instability. The degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) is the major cause of PD motor dysfunction. Currently, α-synuclein accumulation and mitochondrial dysfunction are two most common features and proposed causes of PD parthenogenesis ([@bib48]; [@bib45]; [@bib15]). α-Synuclein is the major component of Lewy bodies and neurites ([@bib39]). It is believed that aggregation of α-synuclein, which can severely impact proteasomes, lysosomes, mitochondria, endoplasmic reticulum (ER), and cell membrane aggregation, triggers the onset of PD ([@bib22]; [@bib59]). As for mitochondria dysfunction, findings from mitochondrial toxins, genetic studies, and patients suggest that it can be one of the general and primary causes of PD ([@bib48]). In fact, α-synuclein accumulation and mitochondrial dysfunction might be linked during PD pathogenesis ([@bib48]).

Iron accumulation is another pathological hallmark of PD. It has been reported by different groups that with disease progression, iron is gradually accumulated in the substantia nigra (SN) in PD patients ([@bib2]; [@bib24]; [@bib38]; [@bib51]; [@bib63]; [@bib87]; [@bib105]). Consistent with this observation, in 6-hydroxydopamine (6-OHDA)- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD animal models, iron levels are elevated in the SN concurrently with dopaminergic neuron loss, whereas iron chelator administration or iron-related gene rectification can ameliorate this impairment ([@bib60]; [@bib95]; [@bib31]; [@bib19]; [@bib55]; [@bib83]). Iron accumulation and neurodegeneration are associated with altered expressions of iron-transport proteins, such as divalent metal transporter 1 (DMT1) with iron responsive element (DMT1+) ([@bib56]; [@bib94]; [@bib108]; [@bib99]; [@bib17]). Increased free iron level causes neuronal damage and death not only via the Fenton reaction ([@bib47]), which generates hydroxyl radicals that oxidize proteins, lipids, and DNA, but also affects the formation of α-synuclein oligomers in the presence of Fe^3+^ through a direct interaction ([@bib67]). We speculate that iron accumulation, especially in free iron form, is a common thread connecting both mitochondrial dysfunction and α-synuclein aggregation in PD and that strategies that manipulate the level of iron would be highly beneficial. However, there is currently no applicable iron-modifying treatment for PD. Iron chelators have been investigated for clinical applications for several decades without success, although several new iron chelators seem to be promising in clinical trials recently ([@bib23]; [@bib78]; [@bib97]).

Hepcidin is a conserved 25-amino acid peptide that plays a key role in regulating iron metabolism ([@bib50]). Hepcidin is mainly produced in the liver to maintain iron homeostasis by regulating iron absorption in the intestine, iron recycling in the spleen, iron storage in the liver, and its utilization in the bone marrow ([@bib50]). Intriguingly, hepcidin is also expressed in the brain. Our previous work has demonstrated that hepcidin decreases iron uptake and release via decreasing the levels of DMT1+, DMT1 without IRE (DMT1−), transferrin receptor (TfR), and Fpn, in various types of cultured cells including astrocytes ([@bib26]), macrophages ([@bib28]), and microvascular endothelial cells ([@bib27]). In cultured neurons, hepcidin decreases DMT1, TfR, Fpn, ferritin-L, and ferritin-H contents ([@bib122]; [@bib27]). Recently, we found that hepcidin reduces brain iron in iron-overloaded rats and suppresses transport of transferrin-bound iron from the periphery into the brain ([@bib27]). Moreover, iron accumulation and oxidative stress are suppressed in the SN in iron-overloaded rats by hepcidin ([@bib40]). However, whether hepcidin plays any role in central nervous system disease including PD is still to be investigated. Given its prominent iron-regulatory effect on brain iron accumulation, we hypothesize that hepcidin overexpression could be a promising strategy for treating PD.

In this study, we determined whether overexpression of hepcidin could rectify Parkinsonian symptoms and pathogenic changes in 6-OHDA- and rotenone-induced models of PD. We then investigated whether the beneficial effects of hepcidin are a result of amelioration of iron dyshomeostasis and other cellular dysfunctions in neurons. We found that hepcidin protects against rotenone-induced mitochondrial deficits by suppressing cellular and mitochondrial iron accumulation. In addition, it was revealed that hepcidin mediates α-synuclein clearance through decreasing iron accumulation and subsequent autophagy activation.

Results {#sec2}
=======

Therapeutic Effects of Hepcidin in PD Animal Models {#sec2.1}
---------------------------------------------------

We studied the potential therapeutic effects of hepcidin in two well-established rat models of PD, namely chronic IP administration of rotenone and acute unilateral 6-OHDA injections into the medial forebrain bundle. Although the neurotoxicology of these two models that lead to Parkinsonian symptoms are different ([@bib8]), iron accumulation is a shared feature ([@bib72]). To assess the effect of hepcidin, we upregulated the expression of endogenous hepcidin in the brain by construction and injection of adenovirus that carries the hepcidin gene (Ad-hepcidin) ([@bib27]). In our previous study, we reported that after ICV injection of Ad-hepcidin, there were similar fold of increase of hepcidin mRNA levels in the cortex, hippocampus, and SN ([@bib40]). The experimental paradigms of these sets of experiments are shown in [Figures 1](#fig1){ref-type="fig"}A and 1B. Overexpression of hepcidin in these two models by injection of Ad-hepcidin was confirmed by immunohistochemistry ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) and ELISA ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Increased intensity of hepcidin was detected in neurons and glia in the SN ([Figure S1](#mmc1){ref-type="supplementary-material"}A).Figure 1Ad-hepcidin Improved Rotenone-Induced Motor Deficiency and Dopaminergic Neuron LossExperimental scheme of rotenone and 6-OHDA model (A and B). Injection of rotenone (IP) induced a significant increase of first-step and descent latencies in grid and bar test, respectively, which was reduced by ICV Ad-hepcidin injection (C and D). In the stepping test, the reduction of adjusting steps induced by rotenone was also improved by Ad-hepcidin, for both the left and right paw (E and F). Tyrosine hydroxylase--positive (TH^+^) neurons in the SNc were significantly reduced in count in rotenone treatment. Ad-hepcidin injection ameliorated TH^+^ neuron loss. Quantitative analysis showed that the effect of Ad-hepcidin was statistically significant. Data were presented as percentage of control; the scale bar represents 200 μm (G and H). Ad-hepcidin injection into SN suppressed apomorphine-induced contralateral rotation in 6-OHDA model of PD (I). In the cylinder test, Ad-hepcidin ameliorated 6-OHDA-induced forelimb use asymmetry (J). ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, one-way ANOVA for C--G, two-tailed t test for I, J (n = 5--15 in each group); error bars, S.E.M.

In the rotenone model, we tested the effects of Ad-hepcidin administration on motor ability of the rat using the catalepsy tests (grid test and bar test), stepping test, rotarod test, and ladder rung walking test 7 weeks after rotenone injection. Compared with the healthy control group, we found that rotenone treatment prolonged first-step latency in the grid test (p \< 0.01) and latency to leave the bar in the bar test (p \< 0.05). Injection of Ad-hepcidin but not the blank AAV (Ad-blank) reversed the prolonged latency in the grid test *(*p \< 0.05, compared with rotenone group) and the bar test (p \< 0.05, compared with rotenone group) ([Figures 1](#fig1){ref-type="fig"}C and 1D). In the stepping test, the numbers of adjusting steps of both the left and right paws were significantly reduced in rotenone-injected rats (p \< 0.01, compared with the respective control). Similarly, Ad-hepcidin, but not Ad-blank, reversed the reduction in adjusting steps caused by rotenone (p \< 0.01, compared with rotenone group) ([Figures 1](#fig1){ref-type="fig"}E and 1F). The beneficial effect of hepcidin overexpression in ameliorating Parkinsonian motor deficits was confirmed by the rotarod test and the ladder rung walking test ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Ad-hepcidin was also administered to normal rats without rotenone injection, and the motor ability of these rats did not differ from controls ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Consistent with these behavioral findings, immunohistochemical staining for tyrosine hydroxylase (TH) at the termination of experiments showed that rotenone caused severe reduction in TH immunoreactivity in the striatum ([Figure S2](#mmc1){ref-type="supplementary-material"}C) and the number of TH-positive neurons in the SN ([Figures 1](#fig1){ref-type="fig"}G and 1H), which could be rescued by Ad-hepcidin, but not Ad-blank, treatment.

In 6-OHDA-injected rats in which the motor function was affected unilaterally, we assessed the effects of hepcidin based on the forelimb cylinder test 2 weeks after 6-OHDA administration and the rotational behavior induced by R-(−)-apomorphine hydrochloride 4 weeks after 6-OHDA administration. Consistent with the rotenone model, upregulation of hepcidin rectified motor deficits in 6-OHDA-lesioned rats ([Figures 1](#fig1){ref-type="fig"}I and 1J). When compared with the unlesioned side, TH neurons were almost completely depleted in the SN of the lesioned side as revealed by TH-immunostaining (p \< 0.001), whereas Ad-hepcidin rescued TH neurons significantly (p \< 0.01) ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E).

Hepcidin Rectifies Iron Accumulation in Models of PD {#sec2.2}
----------------------------------------------------

To investigate the relationship between iron accumulation and hepcidin in the PD models, we determined the level of iron in the SN in rotenone- and 6-OHDA-treated rats and examined the effects of hepcidin. In rotenone-treated rats, neuronal loss was associated with deposition of iron within the SNc, where TH-positive dopaminergic neurons are located ([Figure 2](#fig2){ref-type="fig"}A). The morphology of the iron-stained spots is analogous to that of TH neurons, suggesting iron accumulation in the dopaminergic neurons in SNc. Concomitant with the effect in rescuing TH neuron loss, ICV injection of Ad-hepcidin, but not Ad-blank, suppressed iron accumulation in the SNc ([Figure 2](#fig2){ref-type="fig"}A). Consistently, the total iron level in the SN as measured by GFAAS was higher in rotenone-injected rats compared with control rats (p \< 0.05), whereas Ad-hepcidin rather than Ad-blank rectified the abnormal iron levels (p \< 0.01, compared with rotenone group, [Figure 2](#fig2){ref-type="fig"}B). Therefore, the protection conferred by hepcidin overexpression is likely related to reduced iron accumulation in the cell body of dopaminergic neurons in SNc.Figure 2Ad-hepcidin Suppressed Rotenone-Induced Iron Accumulation in the SN via Regulating Iron-Transport ProteinsTH and iron co-staining revealed that rotenone treatment (IP) caused iron accumulation in the SNc. Ad-hepcidin injection (ICV) resulted in reduced accumulated iron in the SN. The scale bars represent 200 μm (top) and 50 μm (bellow) (A). Rotenone injection induced a significant iron content elevation in the SN, an effect that was blocked by Ad-hepcidin injection (B). DMT1+ and TfR were overexpressed in the SN in rotenone-injected rats. Ad-hepcidin suppressed rotenone-induced overexpression of DMT1+ and TfR (C and E). The levels of DMT1−were not affected by rotenone or Ad-hepcidin (D). Ad-hepcidin, but not rotenone, reduced the level of Fpn in the SN (F). ∗p \< 0.05, ∗∗p \< 0.01, one-way ANOVA (n = 5--10 for each group); error bars, S.E.M.

As iron accumulation and neurodegeneration is associated with altered expressions of iron-transport proteins in several models of PD, we investigated whether the iron-suppressive effect of hepcidin is linked to changes in the levels of iron-transport proteins in the SN. First, by western blot analysis, we found that rotenone-injected rats expressed much higher levels of DMT1+ in the SN (p \< 0.05). Ad-hepcidin injection drastically decreased the DMT1+ levels (p \< 0.01, compared with rotenone group, [Figure 2](#fig2){ref-type="fig"}C), but rotenone and Ad-hepcidin did not affect levels of DMT1− ([Figure 2](#fig2){ref-type="fig"}D). At the same time, the level of TfR was also higher in rotenone-injected rats (p \< 0.05). Ad-hepcidin rather than Ad-blank downregulated TfR expression in rotenone-injected rats to a level that was comparable to that of the control (p \< 0.05, [Figure 2](#fig2){ref-type="fig"}E). In addition, Ad-hepcidin, but not Ad-blank, led to a modest but significant decrease in the level of Fpn, the only iron export protein, in the SN (p \< 0.05), although rotenone treatment did not affect Fpn level ([Figure 2](#fig2){ref-type="fig"}F). Thus, hepcidin could rectify the abnormal expressions of iron-import proteins associated with rotenone-induced Parkinsonism, with a slight suppression of iron export protein, contributing to iron suppression in SN. Ad-hepcidin was also administered to normal rats without rotenone injection, and DMT1+, TfR, and Fpn were found to be decreased compared with controls ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3F).

Similarly, Ad-hepcidin effectively suppressed the iron deposition in the SN induced by 6-OHDA ([Figure S4](#mmc1){ref-type="supplementary-material"}A). The iron repressive effect of hepcidin in 6-OHDA model was confirmed by measurement of iron content in the SN ([Figure S4](#mmc1){ref-type="supplementary-material"}B). As for iron-transport proteins, 6-OHDA induced DMT1+ overexpression in the SN (p \< 0.01), whereas Ad-hepcidin suppressed this effect (p \< 0.01) ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Consistent with the rotenone model, 6-OHDA and hepcidin did not significantly affect DMT1− levels in the SN ([Figure S4](#mmc1){ref-type="supplementary-material"}D). As for TfR, 6-OHDA induced its overexpression in the SN (p \< 0.05), whereas Ad-hepcidin suppressed it (p \< 0.05) ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Fpn was not significantly altered in the SN by 6-OHDA lesion, whereas hepcidin downregulated its level (p \< 0.05, [Figure S4](#mmc1){ref-type="supplementary-material"}F). Therefore, hepcidin also rectifies the abnormal expression of iron transport proteins induced by 6-OHDA, which may account for its iron-suppressive effect in the SN.

We provided further evidence to suggest that the site of these changes were the dopaminergic neurons in the SNc. Thus, double staining of TH and iron transport proteins revealed overexpression of DMT1+ and TfR in the neuronal somata of TH-positive neurons in the SNc in rotenone-treated rats, which was suppressed by Ad-hepcidin but not Ad-blank ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). On the other hand, in rotenone-treated rats, staining intensity of DMT1−was increased in the nucleus of TH^+^ and other neurons, whereas Ad-hepcidin, but not Ad-blank, inhibited this change ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Also, Ad-hepcidin slightly decreased the fluorescence intensity of Fpn in the SN and TH^+^ neurons ([Figure S5](#mmc1){ref-type="supplementary-material"}D). All together, these results show that hepcidin specifically rectifies the anomalous expression of iron-transport proteins in dopaminergic neurons in the SN.

Hepcidin Ameliorates Mitochondrial Deficits in Rotenone-Induced Model of PD {#sec2.3}
---------------------------------------------------------------------------

Rotenone is well known to interfere with electron transport process in the mitochondria and mitochondrial function ([@bib3]; [@bib20]; [@bib46]; [@bib44]; [@bib91]). Hence, we examined the functional integrity of mitochondria in the PD models and the effects of hepcidin treatment. We first confirmed by electron microscopy that, under rotenone treatment, the mitochondria of neurons within the SNc appeared to be damaged in that the cristae were fragmented. Ad-hepcidin, but not Ad-blank, injection ameliorated such rotenone-induced mitochondrial malformation ([Figure 3](#fig3){ref-type="fig"}A). Moreover, in this model, rotenone induced inhibition of complex I activity (p \< 0.05) and depleted ATP (p \< 0.05) in the SN. These parameters were also restored by Ad-hepcidin but not Ad-blank (p \< 0.05, compared with rotenone-treated group; [Figures 3](#fig3){ref-type="fig"}B and 3C).Figure 3Ad-hepcidin Ameliorated Rotenone-Induced Mitochondrial Damage in the SN and the Whole BrainInjection (IP) of rotenone caused severe mitochondrial malformation in the SN. The mitochondrial cristae were incomplete, whereas Ad-hepcidin injection (ICV) prevented the damage as revealed by transmission electron microscopy. The scale bar represents 100 nm (A). Ad-hepcidin rescued rotenone-induced mitochondrial complex I activity inhibition and ATP depletion in the SN. The data of Complex I activity were normalized to control, and the ATP levels were presented by arbitrary fluorescence intensity (B and C). Ad-hepcidin rescued rotenone-induced mitochondrial complex I activity inhibition, membrane potential decrease, and ROS overproduction in isolated mitochondria in rat brain. The data of complex I activity and membrane potential were normalized to controls (D--F). (G) Ad-hepcidin supressed rotenone-induced iron increase in isolated mitochondria in rat brain. ∗p \< 0.05, ∗∗p \< 0.01, one-way ANOVA (n = 5--10 in each group); error bars, S.E.M.

To further pinpoint the site of action of hepcidin with respect to its protective function on the mitochondria, we isolated mitochondria directly from the brain and assessed different parameters. We found that in rotenone-treated animals, mitochondrial complex I activity was severely suppressed and the inner membrane potential significantly decreased (p \< 0.05). On the other hand, ROS production was elevated (p \< 0.05). These effects were largely rectified by Ad-hepcidin, but not Ad-blank, administration (p \< 0.05, compared with rotenone group; [Figures 3](#fig3){ref-type="fig"}D--3F). Interestingly, in rotenone-treated rats, iron content in the isolated mitochondria was increased (p \< 0.05), which was suppressed by Ad-hepcidin but not Ad-blank (p \< 0.001, compared with rotenone group; [Figure 3](#fig3){ref-type="fig"}G), implicating a relationship between mitochondrial iron level and the protective effect of hepcidin on mitochondrial functions.

Hepcidin Rectifies Mitochondrial Deficits via Prevention of Iron Accumulation {#sec2.4}
-----------------------------------------------------------------------------

We hypothesized that cellular and mitochondrial free iron accumulation is a prerequisite of severe mitochondria deficiency in PD, and the iron-repressive function of hepcidin accounts for its mitochondria protective effect. We studied the correlation between intracellular free ferrous iron level and mitochondrial activity by co-staining with Calcein-AM and TMRM in rotenone-treated SH-SY5Y cells. Calcein-AM intensity (green fluorescence) was negatively correlated to divalent ion level (mainly iron), whereas TMRM (red fluorescence) was positively correlated to mitochondrial membrane potential. In our experiments, rotenone treatment led to diminished Calcein-AM and TMRM fluorescence intensity, indicating iron accumulation and mitochondrial functional deficiency in SH-SY5Y cells, whereas co-treatment with hepcidin peptide (100nM) protected rotenone-treated cells from iron accumulation and mitochondrial damage. Importantly, co-treatment with FeSO~4~ (5μM) blocked the effect of hepcidin on both decreasing iron level and protecting mitochondrial activity in these cells ([Figure 4](#fig4){ref-type="fig"}A). Thus, when the iron-suppressive effect of hepcidin was interfered by iron treatment, hepcidin had almost no effect on mitochondrial function.Figure 4Hepcidin Ameliorated Rotenone-Induced Mitochondrial Damage via Suppressing Iron AccumulationSH-SY5Y cells were treated with rotenone with or without hepcidin peptide for 24 h. Cells were co-stained with calcein-AM (green) and TMRM (red). Hepcidin reversed both rotenone-induced iron increase and mitochondrial membrane potential decrease, whereas FeSO~4~ (5μM) treatment blocked the effect of hepcidin on cellular iron level and mitochondrial activity. The scale bar represents 5 μm (A). The SH-SY5Y cells were co-stained with RPA (red) and Rh123 (green). Rotenone treatment caused mitochondrial free ferrous iron accumulation, indicated by decreased RPA signal, whereas hepcidin suppressed these effects. FeSO~4~ blocked the effect of hepcidin on mitochondrial iron level and activity in rotenone-treated cells. The scale bar represents 5 μm (B). The effect of iron treatment on intracellular ferrous iron levels was quantified using the calcein-AM method. FeSO~4~ treatment blocked the effect of hepcidin on iron levels (C). The effect of iron treatment on mitochondrial free ferrous iron levels was measured using RPA. FeSO~4~ treatment blocked the effect of hepcidin on mitochondrial iron levels (D). The cells were incubated with JC-1 dye, and the mitochondrial membrane potential was indicated by the ratio of red/green fluorescence intensity. Hepcidin suppressed rotenone-induced mitochondrial membrane potential decrease, whereas FeSO~4~ blocked the effect of hepcidin on mitochondria. The data were normalized to control (E). ∗p \< 0.05, ∗∗p \< 0.01, one-way ANOVA (n = 5--10 in each group); error bars, S.E.M.

In another set of experiments, we made use of RPA, a red fluorescent dye that can enter mitochondria, and the fluorescence intensity of which is negatively correlated with mitochondrial free iron level ([@bib86]; [@bib92]). We also made use of Rh-123, a green fluorescent dye that can enter mitochondria, and the fluorescent intensity of which is negatively correlated with mitochondrial membrane potential. In rotenone-treated cells, mitochondrial ferrous iron levels were raised, indicated by decreased red fluorescence intensity. Hepcidin peptide effectively prevented mitochondrial free iron accumulation, which was blocked by FeSO~4~ ([Figure 4](#fig4){ref-type="fig"}B). Under this condition, hepcidin also failed to rescue rotenone-induced mitochondrial membrane potential decrease. These findings further support that hepcidin leads to mitochondrial iron decrease and protects mitochondria.

The above observations were verified by quantitative essays. In addition to signal changes of Calcein-AM ([Figure 4](#fig4){ref-type="fig"}C) and RPA intensity ([Figure 4](#fig4){ref-type="fig"}D) for semi-quantifying free ferrous iron level in the cells and mitochondria respectively, JC-1 was used as an indicator of mitochondrial membrane potential ([Figure 4](#fig4){ref-type="fig"}E). Our results confirmed that hepcidin is effective in protecting mitochondria by decreasing cellular and mitochondrial free iron accumulation.

Hepcidin Suppresses α-Synuclein Accumulation by Reducing Iron Accumulation {#sec2.5}
--------------------------------------------------------------------------

A distinct feature of the rotenone model of PD is the presence of α-synuclein accumulation in vulnerable areas of the brain, recapitulating a major pathological hallmark of human Parkinsonism. To test whether hepcidin can protect against α-synuclein accumulation in rotenone-induced rat model of PD, brain sections were co-stained for α-synuclein and TH. As shown in [Figure 5](#fig5){ref-type="fig"}A, in rotenone-treated rats, α-synuclein was expressed in the SNc. TH co-staining showed strong expression of α-synuclein in TH-positive neurons. When examining α-synuclein in higher magnification, we found clear discrete spots of immunofluorescence, suggesting aggregation of this protein within the TH neurons. Treatment with Ad-hepcidin, but not Ad-blank, suppressed rotenone-induced α-synuclein accumulation in TH^+^ neurons.Figure 5Hepcidin Decreased Rotenone-Induced α-Synuclein (A-syn) Accumulation via Decreasing Iron ContentRotenone treatment (IP) caused A-syn accumulation in dopaminergic neurons in the SN, which was suppressed by Ad-hepcidin. The scale bars represent 50 μm (top) and 5 μm (bellow) (A). Proteins in the SN were fractionated by Triton, SDS, and urea. A-syn was increased in the Triton and urea fractions but not the SDS fraction, whereas Ad-hepcidin suppressed A-syn elevation in the Triton and urea fractions (B--D). Rotenone treatment caused A-syn accumulation in SH-SY5Y cells, whereas hepcidin peptide ameliorated it. The scale bars represent 10 μm (top) and 4 μm (bellow) (E). Levels of iron content were increased dramatically in rotenone-treated cells. Hepcidin treatment abrogated rotenone-induced iron increase in SH-SY5Y cells. FeSO~4~ (5μM) treatment blocked hepcidin-medicated iron suppression (F). Hepcidin suppressed rotenone-induced A-syn accumulation in SH-SY5Y cells, an effect that was blocked by FeSO~4~ treatment (G). ∗p \< 0.05, n.s means no significant difference, one-way ANOVA (n = 5--10 in each group); error bars, S.E.M.

Different forms of α-synuclein possess divergent solubility. Triton-soluble fraction represents normal α-synuclein. Some types of small α-synuclein oligomers are triton-insoluble SDS-soluble ([@bib61]), whereas many types of neurotoxic- and pathological-related α-synuclein dimers or oligomers are SDS-resistant ([@bib67]; [@bib61]; [@bib12]; [@bib43]). The increased level of α-synuclein in SDS-resistant urea-soluble fraction also suggests aggregation of α-synuclein, which is a highly disease-associated event in PD patient and transgenic models ([@bib65]; [@bib58]). Thereafter, proteins in the SN were isolated by Triton lysate, followed by SDS and urea. The levels of α-synuclein were elevated in Triton (p \< 0.05) and urea (p \< 0.05) fractions but not SDS fractions in rotenone-treated rats. Ad-hepcidin abrogated rotenone-induced elevation of α-synuclein (p \< 0.05, compared with rotenone group) ([Figures 5](#fig5){ref-type="fig"}B--5D). The above findings were also supported by *in vitro* studies in SH-SY5Y cells with some cells treated with rotenone (20nM) alone or rotenone (20nM) + hepcidin (100nM). Rotenone treatment caused dramatic α-synuclein accumulation in these cells, whereas hepcidin suppressed it ([Figure 5](#fig5){ref-type="fig"}E). Besides, the mRNA levels of α-synuclein was not altered either in the SN of rotenone-treated rats or in SH-SY5Y cells, and hepcidin did not affect mRNA levels of α-synuclein in both models (data not shown). Thus, both *in vitro* and *in vivo* evidence support that hepcidin inhibits α-synuclein accumulation in the rotenone model.

To establish a relationship between α-synuclein and iron accumulation under the effect of rotenone, we exploited the fact that α-synuclein accumulation can be induced in SH-SY5Y cells after prolonged rotenone treatment and that the iron-regulatory effect of hepcidin can be interfered by manipulation of iron content. Thus, in normal SH-SY5Y cells in which treatment with 20 nM of rotenone for more than 3 days caused α-synuclein accumulation (p \< 0.01) ([Figure 5](#fig5){ref-type="fig"}F), a significant rise in cellular iron content was found in parallel (p \< 0.05) ([Figure 5](#fig5){ref-type="fig"}G). Co-treatment with hepcidin suppressed the increases in both α-synuclein and iron content (p \< 0.05). Consistent with the experiments on mitochondria, supplementation of exogenous FeSO~4~ (5μM) eliminated the protective effects of hepcidin (p \< 0.05) ([Figures 5](#fig5){ref-type="fig"}F and 5G). Together, these results strongly implicate that in the rotenone-induced model of PD, hepcidin inhibits α-synuclein accumulation via suppressing iron accumulation.

Hepcidin Mediates α-Synuclein Clearance via Iron Accumulation Suppression and Subsequent Activation of Autophagy {#sec2.6}
----------------------------------------------------------------------------------------------------------------

Because the accumulation, oligomerization, and aggregation of α-synuclein is generally regarded as toxic and could play a key role in the neurodegenerative process occurring in PD, elucidating how hepcidin can promote the clearance of this protein is an important question to address. It is known that some forms of SDS-resistant α-synuclein derives from incomplete autophagic degradation ([@bib43]), and the oligomerized and aggregated forms of α-synuclein are mainly degraded by the autophagy-lysosome system ([@bib29], [@bib30]). Therefore, we asked whether rotenone and hepcidin exert any effect on the autophagy process. The levels of two autophagy markers, P62 and LC3B, were quantified in both the *in vivo* and *in vitro* rotenone models. In rotenone-treated rats, P62 was increased and the ratio of LC3B II/I was decreased in the SN (p \< 0.05, [Figures 6](#fig6){ref-type="fig"}A and 6B), indicating suppression of autophagy. Ad-hepcidin, rather than Ad-blank, reduced P62 and raised the ratio of LC3BII/I, implying that hepcidin could induce autophagy (p \< 0.05, compared with rotenone group, [Figures 6](#fig6){ref-type="fig"}A and 6B). Consistently, in SH-SY5Y cells, rotenone treatment induced an increase in P62 and a decrease in the ratio of LC3BII/I (p \< 0.05). These changes were reversed by hepcidin peptide (100nM) (p \< 0.05 compared with rotenone group, [Figures 6](#fig6){ref-type="fig"}C and 6D). The cells were treated with bafilomycin A1 (Baf A1) (0.2 μM), an inhibitor of the late phase of autophagy, for 8 h before harvest, with increased P62 levels and LC3BII/I ratio in all groups observed. At the same time, Baf A1 failed to block rotenone-induced decrease of LC3BII/I ratio ([Figures 6](#fig6){ref-type="fig"}E and 6F), implying rotenone-induced autophagy initiation inhibition. In rotenone-treated cells, Baf A1 blocked hepcidin-mediated decrease of P62 but not the increase of LC3BII/I ratio (p \< 0.05, compared with rotenone + hepcidin group), suggesting an activation of autophagy initiation by hepcidin ([Figures 6](#fig6){ref-type="fig"}E and 6F). In addition, the fact that addition of FeSO4 could abolish the effect of hepcidin on rotenone-induced changes in these markers (p \< 0.05, compared with rotenone + hepcidin group) suggests the involvement of hepcidin-mediated reduction in iron level in the process ([Figures 6](#fig6){ref-type="fig"}C and 6D), that is, iron accumulation could be a cause of autophagy inhibition.Figure 6Hepcidin Mediated A-syn Clearance via Autophagy ActivationRotenone treatment (IP) caused P62 accumulation and LC3BII/I ratio reduction in the SN, whereas Ad-hepcidin suppressed these effects (A and B). In SH-SY5Y cells, hepcidin suppressed rotenone-induced P62 accumulation and decrease of LC3BII/I ratio, an effect that was blocked by FeSO~4~ (5μM) treatment (C and D). Baf A1 treatment caused P62 accumulation in all four groups, with a more significant rise of P62 in control and rotenone + hepcidin groups compared with the condition of no Baf A1 (C and E). Hepcidin failed to suppress P62 accumulation in rotenone-treated cells under Baf A1 treatment (E). Baf A1 treatment caused a general rise of LC3BII/I ratio in all of four groups (D and F). Hepcidin still increased the ratio of LC3BII/I when cells were treated with rotenone and Baf A1, an effect suppressed by FeSO~4~ (F). Both autophagy inhibitor CQ and 3MA blocked hepcidin-mediated A-syn clearance in rotenone-treated SH-SY5Y cells. The data were normalized to control (G). ∗p \< 0.05, ∗∗p \< 0.01, one-way ANOVA (n = 5--10 in each group); error bars, S.E.M.

To elucidate whether hepcidin-mediated autophagy activation is responsible for α-synuclein clearance, we utilized a rotenone-induced *in vitro* model of PD. Both autophagy inhibitors, chloroquine (CQ) (10μM) and 3-Methyladenine (3MA) (5mM), blocked the effect of hepcidin in reversing rotenone-induced α-synuclein accumulation (p \< 0.05, compared with rotenone + hepcidin group, [Figure 6](#fig6){ref-type="fig"}G). We also did parallel experiments on the proteasome system. As expected, hepcidin failed to ameliorate rotenone-induced inhibition of proteasome activity, and its mediation of α-synuclein clearance could not be blocked by proteasome inhibitor MG132 (2.5μM) in rotenone-treated cells (data not shown). Taken all together, we demonstrate that hepcidin promotes α-synuclein clearance via specific autophagy activation in rotenone models, which is dependent on a reduction of free iron level.

Discussion {#sec3}
==========

In this study, we presented evidence supporting that iron accumulation could be a common thread of two major pathological hallmarks of PD, mitochondrial dysfunction and α-synuclein accumulation. More importantly, we found that suppression of iron accumulation in the brain by overexpression of hepcidin could rectify both mitochondrial dysfunction and α-synuclein accumulation in animal models of PD and achieve a therapeutic effect on motor deficits. The major experimental paradigm for the generation of Parkinsonism in this study is based on chronic administration of rotenone. Rotenone is known not only to cause highly selective nigrostriatal dopaminergic degeneration and motor deficits, including bradykinesia, postural instability, and rigidity, but also to result in fibrillar cytoplasmic inclusions that contain α-synuclein and ubiquitin in dopaminergic neurons of the SN ([@bib7], [@bib6]; [@bib32]; [@bib11]). Furthermore, chronic rotenone treatment on differentiated SH-SY5Y cells reproduces Lewy neurites with accumulated α-synuclein ([@bib9]).

Although mounting evidence suggests that iron is accumulated in the SN together with mitochondrial deficits in PD, the mechanistic link, if any, between these two phenomena has not been established firmly. It has been proposed that proteins containing Fe-S clusters in mitochondria and IRP1 could be the causal link between mitochondrial damage and consequential mitochondrial and cytoplasmic iron increase ([@bib81]; [@bib69]; [@bib14]; [@bib75], [@bib77]). Meanwhile, it had been reported that mitochondrial health and iron homeostasis are co-regulated by Nrf2, a redox-sensitive transcription factor ([@bib4]). However, whether mitochondrial and cytoplasmic labile iron increase is a prerequisite for mitochondria deficits and effective treatment targeting excess iron to rescue mitochondria have not been well explored. In a previous *in vitro* study on midbrain dopaminergic neurons, MPTP induced overexpression of DMT1 and iron influx together with a mitochondria membrane potential decrease, whereas DFO, the iron chelator, abolished all of these effects ([@bib120]). As DFO is unable to pass through the mitochondrial membrane and chelate mitochondrial iron, the protective effect of DFO implies that iron outside the mitochondria exacerbates mitochondrial damage. However, a group recently reported that chelators that mainly decrease mitochondrial iron pool was much more effective than those that decrease the cytoplasmic iron pool, indicating that the mitochondrial iron pool plays a more important role in mitochondrial intoxication ([@bib76]). These studies implicate that excessive free iron accumulation could account for mitochondria deficiency in PD. Our result that hepcidin ameliorated rotenone-induced mitochondrial malformation and deficiency in the SN supports this notion. Thus, natural iron-regulatory protein can be as effective as iron chelators in regulating mitochondrial iron dyshomeostasis. These findings are in line with previous studies showing that mitochondrial ferritin, an iron storage protein specifically located in mitochondria that possesses high homology to H-ferritin ([@bib66]), could protect mitochondria and suppress ROS and dopaminergic neural loss in both 6-OHDA- and MPTP-induced PD models ([@bib96]; [@bib119]).

Our finding on the effects of hepcidin in α-synucleinopathy is of particular interest. Phosphorylated α-synuclein fibrils are the major constituent of Lewy neurites and Lewy bodies, which are the hallmarks of PD. Most α-synuclein in SDS-insoluble urea-soluble fraction is phosphorylated at Ser129, whereas normal α-synuclein in Triton fraction is not ([@bib34]). Except fibrils, phosphorylated α-synuclein dimer that induces mitochondrial deficits is also SDS resistant ([@bib43]). Besides, α-synuclein forms various SDS-resistant oligomers that are toxic to cells, such as species induced by Fe^3+^ or dopamine ([@bib61]; [@bib12]). In the present study, SDS-resistant α-synuclein was elevated in rotenone-treated rats, whereas hepcidin exerted strong suppressive effect, suggesting repression of PD pathogenesis. The interaction between iron accumulation and α-synucleinopathy in PD has also been documented. Iron accumulation occurs in the SN where Lewy bodies are also abundantly present ([@bib68]; [@bib101]), and ferrous and ferric iron are observed to be present in Lewy bodies ([@bib85]). In *ex vivo* experiments, iron directly interacts with α-synuclein and promotes its oligomerization and fibrillization ([@bib57]). Several *in vitro* experiments also imply post-transcriptional regulation of α-synuclein by iron via IRP-IRE signaling pathway ([@bib16]). As for α-synuclein degradation, iron may suppress the proteasomal degradation of α-synuclein by inactivating Parkin ([@bib35]). In this study, we confirmed that iron accumulation is one of the major causes of α-synucleinopathy and found that hepcidin suppressed autophagic flux inhibition via decreasing overloaded free iron, thereby promoting autophagic degradation of α-synuclein. The autophagy-lysosomal pathway is the major pathway for α-synuclein degradation during increased α-synuclein burden or when α-synuclein is aggregated. However, this pathway may be impaired in PD. In sporadic PD patients, the activity of α-galactosidase A, a lysosomal hydrolase, is significantly decreased ([@bib115]). Moreover, it has been widely reported that boosting autophagy promotes α-synuclein clearance and protects neurons in PD models ([@bib21]; [@bib70]; [@bib53]; [@bib52]). In addition, iron chelator DFO induced autophagy and exerted its protective effects in rotenone-treated SH-SY5Y cells ([@bib116]). Taken all together, our results suggest that iron accumulation plays role in autophagy flux inhibition and subsequent α-synuclein accumulation in PD, whereas rectifying iron homeostasis via hepcidin can reduce free iron, activate autophagy, and promote α-synuclein clearance.

The iron-suppressing effect of hepcidin in dopaminergic neurons is predominantly achieved through the suppression of DMT1+ and TfR, the two major iron import proteins, responsible for non-transferrin bound iron and transferrin bound iron import, respectively. In fact, both DMT1+ and TfR have consistently been implicated in human PD as well as animal models of PD ([@bib56]; [@bib1]; [@bib54]; [@bib94]). The inhibitory effect of hepcidin on iron uptake in neurons have been reported by us previously ([@bib122]; [@bib27]), and the mechanism may be the same as in astrocytes and macrophages, which is via cAMP-PKA pathway ([@bib26], [@bib28]). Fpn is the only identified iron export protein as well as the target of hepcidin located on the cell membrane. However, hepcidin-mediated Fpn reduction in dopaminergic neurons does not appear to contribute to the effect. Despite some studies revealing coincidence of changed Fpn levels in the SN and the fate of dopaminergic neurons ([@bib118]; [@bib64]; [@bib33]; [@bib71]; [@bib121]) in PD models and the detrimental effect of Fpn silencing in 6-OHDA-treated cultured cells ([@bib100]), there are other studies showing that Fpn deletion has no apparent consequence on dopaminergic neurons in the SN in mice ([@bib73]). Ferrous iron is exported by Fpn following oxidation by ceruloplasmin (CP), a protein that has been shown to be associated with PD ([@bib112]). However, the link between CP and Fpn in dopaminergic degeneration is not clear and worth to be investigated in the future. Secondly, hepcidin still suppresses iron uptake in iron-depleted cells, indicating that the inhibitory effect of hepcidin on iron uptake is not a feedback of hepcidin-mediated Fpn degradation and subsequent iron increase ([@bib26]). Thirdly, cyclic adenosine monophosphate is normally a second messenger response to hormone receptors located on the membrane of target cell ([@bib88]), which implies the existence of an unidentified receptor of hepcidin. Except repressing iron uptake in dopaminergic neurons, given that hepcidin reduces iron transport across the blood-brain barrier (BBB) in normal and iron overload conditions via regulating DMT1 and TfR ([@bib27]; [@bib74]), as proposed in a "bypass model"([@bib27]; [@bib88]), and the properties of the BBB are altered in PD ([@bib103]), it is probable that hepcidin ameliorates rotenone-induced neuronal degeneration and iron accumulation partially via suppressing iron import into brain. In summary, although Ad-hepcidin also decreased Fpn expression, we found that suppression of iron influx is the overwhelming effect of hepcidin in the SN. Nevertheless, to establish a clear causal relation between hepcidin-mediated iron reduction and other beneficial effects of hepcidin, identifying the receptor of hepcidin or manipulation of hepcidin-regulated iron proteins is warranted in future studies.

As an endogenous cationic hormone containing 25 amino acids, it has been reported that hepcidin can cross the BBB ([@bib89]; [@bib117]; [@bib111]), although the permeability is not yet determined. To increase the penetration rate across the BBB, hepcidin can be conjugated with plasma membrane transducing domains ([@bib82]), or ligands targeting receptors on the BBB, notably transferrin or TfR monoclonal antibodies ([@bib5]; [@bib84]). Alternative approaches that are potentially feasible include delivery by nanoparticles ([@bib42]; [@bib5]) and the use of hepcidin agonists ([@bib13]).

It is noteworthy that hepcidin has a dual role in diseases associated with inflammation and iron overload ([@bib111]). Hepcidin is an antimicrobial peptide that is overproduced under infection, inflammation, and stress as an innate defense mechanism. A consensus on whether hepcidin overexpression in different disease models is beneficial or detrimental has not been reached. For example, hepcidin could exacerbate brain damage in ischemic or hemorrhagic stroke ([@bib104]; [@bib25]; [@bib117]), whereas it has been reported to be protective in iron overload condition and Alzheimer disease (AD) ([@bib40]; [@bib109]). One possibility is that the timing of hepcidin is critical, being beneficial mainly in pre-treatment ([@bib111]). However, given that we did not pre-treat hepcidin in our model, differences in the nature of disease may account for the observed differences. Specifically, stroke is a disease with acute and severe damage to BBB and neurons, whereas in neurodegenerative diseases neurons are damaged chronically usually with years of progression. Inflammation is far more severe in stroke than in neurodegenerative diseases ([@bib113]; [@bib80]; [@bib102]), with notable differences in roles of immunocytes between ischemic stroke and neurodegenerative diseases ([@bib93]; [@bib123]; [@bib98]; [@bib41]; [@bib10]; [@bib62]; [@bib18]). Given that AD and PD share some common mechanisms of iron metabolism and hepcidin is also decreased in the brain in AD animal models and patients ([@bib90]), it is reasonable to speculate a similar protective role of hepcidin in PD. Also, it is possible that microglia, astrocytes, and the peripheral immune system all contribute to neurotoxin-induced dopaminergic neuronal degeneration. Inflammation could be triggered by mitochondrial damage and α-synucleinopathy ([@bib37]; [@bib36]; [@bib106]) and acts as an amplifier of degenerative events including aggravating mitochondrial damage and iron accumulation in neurons via cytokines, ROS, and TLRs signal in PD ([@bib110]; [@bib107]). Nonetheless, our *in vitro* experiments demonstrated effectiveness of hepcidin on cultured neurons. Meanwhile, 6-OHDA and rotenone not only primarily and selectively damage dopaminergic neurons *in vivo* but also cause neurodegeneration and iron accumulation without glia in *in vitro* studies ([@bib79]; [@bib114]; [@bib75]; [@bib54]). Moreover, a direct pathway from mitochondria dysfunction to Fe-S proteins-mediated iron accumulation in neurons without involvement of inflammation in early steps has been reported ([@bib110]; [@bib81]; [@bib77]). Thus, a direct action on dopaminergic neurons rather than glia is believed to be a more important protective mechanism of hepcidin in the present study.

In conclusion, our study demonstrates the beneficial effect of hepcidin in PD animal models and elucidates the mechanism in neurons, which is summarized in [Figure 7](#fig7){ref-type="fig"}. On a broader perspective, our study confirms the detrimental effect of iron overload in the pathogenic process of Parkinsonism. Rectifying iron dyshomeostasis via manipulation of hepcidin level in the brain could suppress iron accumulation and other major pathologies of PD and therefore represents a promising therapeutic direction.Figure 7A Model of Mechanism of Action of HepcidinRotenone treatment causes mitochondrial damage and iron accumulation in dopaminergic neurons in the substantia nigra. Iron accumulation exacerbates mitochondrial damage. At the same time, overloaded iron results in autophagy inhibition leading to alpha-synuclein (A-syn) accumulation (A). The major action of hepcidin is the abrogation of rotenone-induced iron increase. Consequently, mitochondrial damage is ameliorated, and A-syn is degraded by the activation of autophagy (B).

Limitations of the Study {#sec3.1}
------------------------

As discussed earlier, the limitation of present study is that whether the beneficial effect of hepcidin on dopaminergic neurons is also via modulation of inflammation in PD. Besides, the contribution of glia cells in the protective process is not experimentally addressed.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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